Neuphoria Therapeutics Inc.

8-K Entered a material agreement; Change in control; Regulation FD disclosure Jul 24, 2026 8-K Other events May 26, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 10-Q Quarter ended 2025-12-31 Feb 17, 2026 8-K Entered a material agreement; Terminated a material agreement Jan 8, 2026 8-K Delisting notice or listing-rule failure Dec 18, 2025 8-K Shareholder vote results Dec 17, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Entered a material agreement; Modified rights of security holders; Amended charter or bylaws; Other events Oct 27, 2025 8-K Other events Oct 20, 2025 10-K Fiscal year ended 2025-06-30 Sep 29, 2025 8-K Delisting notice or listing-rule failure Sep 16, 2025 8-K Delisting notice or listing-rule failure Jul 18, 2025 8-K Results of operations (earnings release) May 20, 2025 10-Q Quarter ended 2025-03-31 May 20, 2025 10-Q Quarter ended 2024-12-31 Feb 14, 2025 8-K Other events Jan 14, 2025 8-K Entered a material agreement; Delisting notice or listing-rule failure; Unregistered sale of equity; Modified rights of security holders; Change in control; Director or officer change; Amended charter or bylaws; Item 5.05; Other events Dec 23, 2024 8-K Other events Dec 16, 2024 8-K Shareholder vote results Dec 12, 2024 8-K Entered a material agreement Nov 21, 2024 10-Q Quarter ended 2024-09-30 Nov 14, 2024 8-K Other events Nov 8, 2024 8-K Director or officer change Oct 10, 2024 8-K Entered a material agreement Oct 2, 2024 10-K Fiscal year ended 2024-06-30 Sep 30, 2024 8-K Delisting notice or listing-rule failure Jul 16, 2024 6-K Jun 3, 2024 6-K Mar 15, 2024 20-F/A Jan 17, 2024 6-K Jan 4, 2024 6-K Nov 30, 2023 6-K Nov 28, 2023 6-K Nov 3, 2023 20-F Oct 18, 2023 6-K Oct 16, 2023 6-K Sep 29, 2023 6-K Sep 28, 2023 6-K Jul 31, 2023 6-K Jul 28, 2023